Medicare Part D in 2026: Drug Costs, the $2,100 Cap, and What Changed

Medicare Part D drug coverage went through its most significant redesign in program history in 2025 and 2026. The most important change: a hard $2,100 annual cap on out-of-pocket prescription drug costs, up from $2,000 in 2025. Once you spend $2,100 on covered drugs in a calendar year, you pay nothing for the rest of the year. On top of that, 2026 marks the first year negotiated drug prices take effect for 10 high-cost medications, including Eliquis, Jardiance, and Xarelto.

What Is the New $2,100 Out-of-Pocket Cap?

The annual out-of-pocket cap eliminates what was previously called the 'coverage gap' or 'donut hole' — a design flaw where beneficiaries faced sharply higher drug costs mid-year. Starting in 2025 and continuing in 2026, the benefit structure is simplified: you pay a deductible (up to $615 in 2026), then cost-sharing on covered drugs, and once your total out-of-pocket spending reaches $2,100, you pay $0 for all covered drugs for the rest of the year.

This cap is especially meaningful for people who take expensive medications for cancer, autoimmune diseases, heart failure, or diabetes — conditions where annual drug costs previously could reach $10,000 or more.

Which Drugs Were Negotiated for Lower Prices in 2026?

Under the Inflation Reduction Act, Medicare negotiated directly with drug manufacturers for the first time ever. The 10 drugs with negotiated 'Maximum Fair Prices' effective January 1, 2026 are: Eliquis (blood clots, stroke prevention), Jardiance (type 2 diabetes, heart failure), Xarelto (blood clots), Januvia (type 2 diabetes), Farxiga (diabetes, heart failure, kidney disease), Entresto (heart failure), Enbrel (rheumatoid arthritis, psoriasis), Imbruvica (certain blood cancers), Stelara (Crohn's disease, psoriasis), and NovoLog/Fiasp (insulin).

CMS projects these negotiated prices will save Medicare Part D enrollees approximately $1.5 billion in out-of-pocket costs in 2026. Discounts range from 38% to 79% off list prices. However, your actual copay depends on how your specific plan classifies each drug on its formulary — a drug with a lower negotiated price may still sit on a higher tier with significant cost-sharing.

What Is the Medicare Prescription Payment Plan?

Starting in 2025, all Part D plans must offer the Medicare Prescription Payment Plan, which allows you to spread your out-of-pocket drug costs into equal monthly payments rather than paying a large lump sum at the pharmacy early in the year. If you take expensive medications and typically hit the out-of-pocket cap by February or March, this smoothing feature can provide meaningful cash flow relief.

How Did Part D Change From 2025 to 2026?

What Improved in 2026

•  Out-of-pocket cap rises modestly to $2,100 (from $2,000 in 2025)

•   Negotiated drug prices take effect for 10 high-cost medications

•   Medicare Prescription Payment Plan continues — spread costs monthly

•   No cost-sharing once the $2,100 cap is reached

•   15 additional drugs added to negotiation list for 2027

What to Watch Out For

•   Maximum Part D deductible increases to $615 (up from $590 in 2025)

•   Plan premiums rose as insurers adapt to new cost-sharing structure

•   Negotiated price does not automatically mean lower copay — depends on plan formulary tier

•   Fewer plans available in 2026 as some insurers exited the market

•   Always review your plan annually — formularies change every year

Should You Review Your Part D Plan Every Year?

Yes — this is one of the most important Medicare decisions you can make annually. Part D plans change their formularies, tier placements, and premiums each year. A drug that was on Tier 2 (low copay) in 2025 may have moved to Tier 4 (high cost-sharing) in 2026. Always use the Annual Election Period (October 15 – December 7) to review whether your current plan still offers the best coverage for your specific medications.

Medicare's Plan Finder tool at medicare.gov can identify the lowest total cost plan for your drug list. A licensed broker can do this analysis for you at no cost and help you enroll in the best option.

Frequently Asked Questions

Q: Does the $2,100 cap apply to Medicare Advantage drug plans?

Yes. The $2,100 out-of-pocket cap applies to both standalone Part D plans and Medicare Advantage plans that include drug coverage (MAPD plans).

Q: Are insulin costs capped under Part D?

Yes. Insulin covered under Part D is capped at $35 per month per product, regardless of the plan's deductible or the drug's tier placement.

Q: What happens if my drug is not on my plan's formulary?

You can request a formulary exception from your plan, ask your doctor about therapeutic alternatives that are covered, or switch to a plan that covers your medication during the Annual Election Period.

Q: Do the negotiated drug prices apply to Medicare Advantage plans?

Yes. Medicare Advantage plans with drug coverage must include the 10 negotiated drugs on their formularies and make the Maximum Fair Prices available to eligible beneficiaries.

Key Takeaways

•  The 2026 Part D out-of-pocket cap is $2,100 — once reached, covered drugs cost you nothing for the rest of the year.

•  10 high-cost drugs have federally negotiated lower prices effective January 1, 2026.

•  Your actual copay still depends on your plan's formulary tier — a lower negotiated price does not guarantee a lower copay.

•  The Medicare Prescription Payment Plan lets you spread drug costs over monthly payments.

•  Review your Part D plan every year during Annual Election Period (Oct 15–Dec 7).

Sources & References

• Centers for Medicare & Medicaid Services. Medicare Drug Price Negotiation Program: Negotiated Prices for Initial Price Applicability Year 2026. cms.gov

• CMS. 2026 Medicare Parts A & B Premiums and Deductibles. cms.gov

• AARP. 3 Prescription Drug Changes Coming to Medicare in 2026. aarp.org

• Medicare Rights Center. Negotiated Prices Take Effect for Ten Drugs in 2026. medicarerights.org